The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

A high burden of infectious diseases coexists with a rapid rise in non-communicable diseases such as diabetes, cancer, and ...

For Lebrat, it goes back to simplicity of use: the synthetic persona leverages the data a team already has. Synthetic ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...

Finally, New York's Gilgamesh Pharma – a spinout company formed when AbbVie bought Gilgamesh Pharmaceuticals and its ...

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. The new results come from the EMERALD-3 study, testing a ...

Sebnem Avsar Tuna, general manager of Novo Nordisk UK, reflected on how advances in biology and research have helped reshape ...

For Korsana, merging with Cyclerion gives it a fast track to a Nasdaq listing without the complexities of going down the IPO ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

In a subgroup of black women enrolled in a US breast cancer registry called BEST, women deemed to have low-risk tumours using the MammaPrint test had a 97.7% recurrence-free rate after 10 years, the ...

"Through the integration of virtual control groups, EMA also seeks to improve the relevance and predictability of ...

Three behavioural phenomena are particularly consequential in screening and prevention research: ...